Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and meraquinone metabolic pathways?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 6, 2014, Pages 691-701

  Hong, Weiling ^a   Chen, Lifang ^a   Xie, Jianping ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

D cycloserine; Drug resistance; Drug target; Mycobacterium tuberculosis

Indexed keywords

ALANINE RACEMASE; CYCLOSERINE; DEXTRO ALANINE; MERAQUINONE; PEPTIDOGLYCAN; QUINONE DERIVATIVE; UBIQUINONE; UNCLASSIFIED DRUG; ALANINE; FARNOQUINONE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; BACTERIAL METABOLISM; DRUG TARGETING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SEQUENCE ANALYSIS; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; MOLECULAR GENETICS;

ALANINE; AMINO ACID SEQUENCE; CYCLOSERINE; DRUG RESISTANCE, BACTERIAL; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; PEPTIDOGLYCAN; UBIQUINONE; VITAMIN K 2;

EID: 84900806061     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.902937     Document Type: Review

References (77)

1. Ramsey D, Cowan P. Mortality rate and movements of brushtail possums with clinical tuberculosis (Mycobacterium bovis) infection. N Z Vet J 2003;51:179-85
2. Nugent G, Yockney I, Whitford J, et al. Mortality rate and gross pathology due to tuberculosis in wild brushtail possums (Trichosurus vulpecula) following low dose subcutaneous injection of Mycobacterium bovis. Prev Vet Med 2013;109(1-2):168-75
3. Mishra B, Rockey SM, Gupta S, et al. Multi-drug-resistant tuberculosis: the experience of an urban tertiary care hospital in South India using automated BACTEC 460 TB. Trop Doct 2012;42:35-7
4. Tsuyuguchi I. [Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)-its feasibility]. Kekkaku 1999;74:479-91
5. Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:897-900
6. Pavan FR, Poelhsitz GV, da Cunha LV, et al. In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis. PLoS One 2013;8:e64242
7. Amaral L. Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Med Port 2012;25:118-21
8. Seddon JA, Donald PR, Vlok GJ, et al. Multidrug-resistant tuberculosis of the spine in children-characteristics from a high burden setting. J Trop Pediatr 2012;58:341-7
9. Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 2008;6:41-52
10. Nanninga N. Morphogenesis of Escherichia coli. Microbiol Mol Biol Rev 1998;62:110-29
11. Alderwick LJ, Birch HL, Mishra AK, et al. Structure, function and biosynthesis of the Mycobacterium tuberculosis cell wall: arabinogalactan and lipoarabinomannan assembly with a view to discovering new drug targets. Biochem Soc Trans 2007;35(Pt 5):1325-8
12. Trias J, Benz R. Permeability of the cell wall of Mycobacterium smegmatis. Mol Microbiol 1994;14:283-90
13. Mahapatra S, Scherman H, Brennan PJ, et al. N Glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment. J Bacteriol 2005;187:2341-7
14. Kotani S, Yanagida I, Kato K, et al. Studies on peptides, glycopeptides and antigenic polysaccharide-glycopeptide complexes isolated from an L-11 enzyme lysate of the cell walls of Mycobacterium tuberculosis strain H37Rv. Biken J 1970;13:249-75
15. Lederer E, Adam A, Ciorbaru R, et al. Cell walls of Mycobacteria and related organisms; chemistry and immunostimulant properties. Mol Cell Biochem 1975;7:87-104
16. Scheffers DJ, Pinho MG. Bacterial cell wall synthesis: new insights from localization studies. Microbiol Mol Biol Rev 2005;69:585-607
17. Pavelka MS Jr, Jacobs WR Jr. Biosynthesis of diaminopimelate, the precursor of lysine and a component of peptidoglycan, is an essential function of Mycobacterium smegmatis. J Bacteriol 1996;178:6496-507
18. Scheurwater EM, Burrows LL. Maintaining network security: how macromolecular structures cross the peptidoglycan layer. FEMS Microbiol Lett 2011;318:1-9
19. Schleifer KH, Kandler O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev 1972;36:407-77
20. Neuhaus FC. The enzymatic synthesis of D-alanyl-D-alanine. II. Kinetic studies on D-alanyl-D-alanine synthetase. J Biol Chem 1962;237:3128-35
21. Smrt J, Beranek J, Sicher J, et al. Synthesis of L-4-amino-3- isoxazolidinone, the unnatural stereoisomer of cycloserine and its antibiotic activity. Experientia 1957;13:291
22. Thorsteinsson T, Masson M, Jarvinen T, et al. Cycloserine fatty acid derivatives as prodrugs: synthesis, degradation and in vitro skin permeability. Chem Pharm Bull (Tokyo) 2002;50:554-7
23. van Heijenoort J. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat Prod Rep 2001;18:503-19
24. Brun J, Viallier J, Cayre RM. [Research on the in vitro activity exercised by cycloserine on Mycobacterium tuberculosis]. C R Seances Soc Biol Fil 1956;150(8-9):1553-5
25. Zawadzke LE, Bugg TD, Walsh CT. Existence of two D-alanine:D-alanine ligases in Escherichia coli: cloning and sequencing of the ddlA gene and purification and characterization of the DdlA and DdlB enzymes. Biochemistry 1991;30:1673-82
26. Li X, Meng X, Duan H, et al. Original and efficient synthesis of D-cycloserine. Arch Pharm (Weinheim) 2010;343:473-5
27. Singh R. A Bio-chemical and Microbiological Appraisal on the Stability of the Second-line Anti-Tuberculosis Drug, Cycloserine in Mycobacterium tuberculosis. J Pure Appl Microbiol 2012;6:209
28. Nitsche MA, Jaussi W, Liebetanz D, et al. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology 2004;29:1573-8
29. Anthony KG, Strych U, Yeung KR, et al. New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis. PLoS One 2011;6:e20374
30. Bruning JB, Murillo AC, Chacon O, et al. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother 2011;55:291-301
31. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995;64:29-63
32. Lederer E. The mycobacterial cell wall. Pure Appl Chem 1971;25:135-65
33. Feng Z, Barletta RG. Roles of Mycobacterium smegmatis D-alanine: D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 2003;47:283-91
34. Halouska S, Chacon O, Fenton RJ, et al. Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase. J Proteome Res 2007;6:4608-14
35. Caceres NE, Harris NB, Wellehan JF, et al. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol 1997;179:5046-55
36. Diven WF, Johnston RB, Scholz JJ. Evidence for the participation of FAD in the alanine racemase (EC 5.1.1.1) reaction. Biochim Biophys Acta 1963;67:161-3
37. Milligan DL, Tran SL, Strych U, et al. The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. J Bacteriol 2007;189:8381-6
38. Lee Y, Mootien S, Shoen C, et al. Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones. Biochem Pharmacol 2013;86:222-30
39. Dickinson JM, Mitchison DA. Activity of the combination of fludalanine and cycloserine against mycobacteria in vitro. Tubercle 1985;66:109-15
40. Kim MG, Strych U, Krause K, et al. N(2)-substituted D, L-cycloserine derivatives: synthesis and evaluation as alanine racemase inhibitors. J Antibiot (Tokyo) 2003;56:160-8
41. Tripathi RP, Tripathi R, Tiwari VK, et al. Synthesis of glycosylated beta-amino acids as new class of antitubercular agents. Eur J Med Chem 2002;37:773-81
42. Kollonitsch J, Barash L. Organofluorine synthesis via photofluorination: 3-fluoro-D-alanine and 2-deuterio analogue, antibacterials related to the bacterial cell wall. J Am Chem Soc 1976;98:5591-3
43. Awasthy D, Bharath S, Subbulakshmi V, et al. Alanine racemase mutants of Mycobacterium tuberculosis require D-alanine for growth and are defective for survival in macrophages and mice. Microbiology 2012;158(Pt 2):319-27
44. Chacon O, Feng Z, Harris NB, et al. Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth. Antimicrob Agents Chemother 2002;46:47-54
45. LeMagueres P, Im H, Ebalunode J, et al. The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. Biochemistry 2005;44:1471-81
46. Strych U, Penland RL, Jimenez M, et al. Characterization of the alanine racemases from two mycobacteria. FEMS Microbiol Lett 2001;196:93-8
47. Shaw JP, Petsko GA, Ringe D. Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9-A resolution. Biochemistry 1997;36:1329-42
48. Morollo AA, Petsko GA, Ringe D. Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase. Biochemistry 1999;38:3293-301
49. LeMagueres P, Im H, Dvorak A, et al. Crystal structure at 1.45 A resolution of alanine racemase from a pathogenic bacterium, Pseudomonas aeruginosa, contains both internal and external aldimine forms. Biochemistry 2003;42:14752-61
50. Skedelj V, Arsovska E, Tomasic T, et al. 6-Arylpyrido[2, 3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial D-alanine:D-alanine ligase. PLoS One 2012;7:e39922
51. Vehar B, Hrast M, Kovac A, et al. Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase. Bioorg Med Chem 2011;19:5137-46
52. Triola G, Wetzel S, Ellinger B, et al. ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds. Bioorg Med Chem 2009;17:1079-87
53. Kovac A, Konc J, Vehar B, et al. Discovery of new inhibitors of D-alanine: D-alanine ligase by structure-based virtual screening. J Med Chem 2008;51:7442-8
54. Kovac A, Majce V, Lenarsic R, et al. Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl). Bioorg Med Chem Lett 2007;17:2047-54
55. Liu S, Chang JS, Herberg JT, et al. Allosteric inhibition of Staphylococcus aureus D-alanine:D-alanine ligase revealed by crystallographic studies. Proc Natl Acad Sci USA 2006;103:15178-83
56. Fan C, Moews PC, Walsh CT, et al. Vancomycin resistance: structure of D-alanine:D-alanine ligase at 3 A resolution. Science 1994;266:439-43
57. Neuhaus FC. Role of the omega loop in specificity determination in subsite 2 of the D-alanine:D-alanine (D-lactate) ligase from Leuconostoc mesenteroides: a molecular docking study. J Mol Graph Model 2011;30:31-7
58. Prosser GA, de Carvalho LP. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine: D-alanine ligase by the antibiotic D-cycloserine. FEBS J 2013;280:1150-66
59. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007;104:5596-601
60. Garcia Pelayo MC, Uplekar S, Keniry A, et al. A comprehensive survey of single nucleotide polymorphisms (SNPs) across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the genealogy and defines a minimal set of SNPs that separate virulent M. bovis strains and M. bovis BCG strains. Infect Immun 2009;77:2230-8
61. Goh KS, Rastogi N. Rapid preliminary differentiation of species within the Mycobacterium tuberculosis complex: proposition of a radiometric method. Res Microbiol 1991;142:659-65
62. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003;48:77-84
63. Feher T, Cseh B, Umenhoffer K, et al. Characterization of cycA mutants of Escherichia coli. An assay for measuring in vivo mutation rates. Mutat Res 2006;595(1-2):184-90
64. Schneider F, Kramer R, Burkovski A. Identification and characterization of the main beta-alanine uptake system in Escherichia coli. Appl Microbiol Biotechnol 2004;65:576-82
65. Anfora AT, Welch RA. DsdX is the second D-serine transporter in uropathogenic Escherichia coli clinical isolate CFT073. J Bacteriol 2006;188:6622-8
66. Cosloy SD. D-serine transport system in Escherichia coli K-12. J Bacteriol 1973;114:679-84
67. Russell RR. Mapping of a D-cycloserine resistance locus in escherichia coli K-12. J Bacteriol 1972;111:622-4
68. Baisa G, Stabo NJ, Welch RA. Characterization of Escherichia coli D-cycloserine transport and resistant mutants. J Bacteriol 2013;195:1389-99
69. WHO. Global Tuberculosis Report 2013. Euro Surveill 2013;18(43)
70. Peters J, De Vries TJ. D-cycloserine administered directly to infralimbic medial prefrontal cortex enhances extinction memory in sucrose-seeking animals. Neuroscience 2013;230:24-30
71. Watson GB, Bolanowski MA, Baganoff MP, et al. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 1990;510:158-60
72. Krystal JH, Petrakis IL, Limoncelli D, et al. Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. Neuropsychopharmacology 2011;36:701-10
73. Yew WW, Leung CC. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008;13:21-46
74. Khalil RB. Non-antidepressant psychopharmacologic treatment of specific phobias. Curr Clin Pharmacol 2013. [Epub ahead of print]
75. Davis M. NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin Neurosci 2011;13:463-74
76. Kayser V, Latremoliere A, Hamon M, et al. N-methyl-D-aspartate receptor-mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor stimulation in a rat model of trigeminal neuropathic pain. Eur J Pain 2011;15:451-8
77. Millecamps M, Centeno MV, Berra HH, et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. Pain 2007;132(1-2):108-23